Journal of neurology
-
Status epilepticus occurs on the intensive care unit, either because the patient has been transferred with refractory status epilepticus or as an incidental finding. Management of refractory status epilepticus on the intensive care unit is necessary for adequate treatment of the physiological compromise that occurs in convulsive status epilepticus. In addition, anaesthesia is sometimes necessary for the treatment of status epilepticus, and provided that the potential benefit of anaesthesia offsets the associated morbidity, then such an approach is warranted. ⋯ Status epilepticus is also under-recognised as a cause of persistent coma on the intensive care unit, though the gain from aggressive treatment in this situation is unknown. In most instances, status epilepticus in coma carries such a poor prognosis that aggressive treatment is probably justified. Myoclonic status epilepticus also occurs on the intensive care unit, usually following cardiorespiratory arrest; this does not necessarily represent an agonal event especially if the initial insult was hypoxia related.
-
Journal of neurology · Apr 2003
An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
Riluzole is the only therapy proven in clinical trials to prolong amyotrophic lateral sclerosis (ALS) survival (approximately three months). Questions remain concerning riluzole's effectiveness in everyday practice, the appropriate duration of treatment, which certain subtypes of ALS specifically benefit from the medication, and whether early administration prolongs survival in ALS patients. We report the results of a population-based outcome study of riluzole in the Irish ALS population over a five-year period. ⋯ This beneficial effect is transient and stopping the medication in advanced ALS should be reconsidered. Bulbar-onset patients appear to particularly benefit from riluzole for unclear reasons. Our initial observations support riluzole use in early ALS.
-
Journal of neurology · Feb 2003
Clinical TrialBilateral subthalamic stimulation effects on oral force control in Parkinson's disease.
Dysarthria in Parkinson's disease (PD) consists of articulatory, phonatory and respiratory impairment. Bilateral subthalamic nucleus (STN) stimulation greatly improves motor disability, but its long-term effect on speech within a large group of patients has not been precisely evaluated. The aim of this study was to determine the effect of bilateral STN stimulation on oral force control in PD. ⋯ However, dysarthria evaluated by the UPDRS was worse in two subgroups of patients with a one to two year and three to five year post-surgical follow-up, in comparison with a subgroup of patients with a three month follow-up. STN stimulation has a beneficial long-term effect on the articulatory organs involved in speech production, and this indicates that parkinsonian dysarthria is associated, at least in part, with an alteration in STN neuronal activity. Nevertheless, to confirm the persistence of the beneficial effect of STN stimulation on parkinsonian dysarthria, a longitudinal evaluation is still needed.
-
Journal of neurology · Feb 2003
Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin.
Botulinum toxin A (BoNT/A) has been used therapeutically to treat muscular hypercontractions and sudomotor hyperactivity. There is increasing evidence that BoNT/A might also have analgesic properties, in particular in headache. In the present investigation we tested the often cited hypothesis that BoNT/A-induced analgesia can be attributed to inhibition of neuropeptide release from nociceptive nerve fibers. ⋯ In conclusion our results indicate that peripheral neuropeptide release is attenuated by BoNT/A. In contrast, the analgesic effect of BoNT/A was very limited. Therefore we assume that other than neuropeptide mechanisms must be important for BoNT/A induced pain relief in clinical pain syndromes.
-
Journal of neurology · Jan 2003
The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study.
In 10-15 % of patients with multiple sclerosis (MS), the clinical course is characterized by slow progression in disability without relapses (primary progressive (PP) MS). The mechanism of disability in this form of MS is poorly understood. Using magnetization transfer ratio (MTR) imaging, we investigated normal appearing white matter (NAWM) and normal appearing grey matter (NAGM) in PPMS and explored the relationship of MTR measures with disability. ⋯ There appear to be significant abnormalities in the NAGM in PP MS. Further investigation of the pathological basis and functional significance of grey matter abnormality in PPMS is warranted.